| Year |
Citation |
Score |
| 2023 |
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. CTLA-4 tail fusion enhances CAR-T antitumor immunity. Nature Immunology. PMID 37500885 DOI: 10.1038/s41590-023-01571-5 |
0.665 |
|
| 2023 |
Zhang L, Park JJ, Dong MB, Arsala D, Xia S, Chen J, Sosa D, Atlas JE, Long M, Chen S. Human gene age dating reveals an early and rapid evolutionary construction of the adaptive immune system. Genome Biology and Evolution. PMID 37170918 DOI: 10.1093/gbe/evad081 |
0.705 |
|
| 2023 |
Dong MB, Tang K, Zhou X, Shen J, Chen K, Kim HR, Zhou J, Cao H, Vandenbulcke E, Zhang Y, Chow RD, Du A, Suzuki K, Fang SY, Majety M, et al. Cas12a/Cpf1 knock-in mice enable efficient multiplexed immune cell engineering. Biorxiv : the Preprint Server For Biology. PMID 36993642 DOI: 10.1101/2023.03.14.532657 |
0.79 |
|
| 2023 |
Zhou X, Cao H, Fang SY, Chow RD, Tang K, Majety M, Bai M, Dong MB, Renauer PA, Shang X, Suzuki K, Levchenko A, Chen S. CTLA-4 tail fusion enhances CAR-T anti-tumor immunity. Biorxiv : the Preprint Server For Biology. PMID 36993364 DOI: 10.1101/2023.03.14.532655 |
0.672 |
|
| 2022 |
Bock C, Datlinger P, Chardon F, Coelho MA, Dong MB, Lawson KA, Lu T, Maroc L, Norman TM, Song B, Stanley G, Chen S, Garnett M, Li W, Moffat J, et al. High-content CRISPR screening. Nature Reviews. Methods Primers. 2. PMID 37214176 DOI: 10.1038/s43586-022-00098-7 |
0.649 |
|
| 2022 |
Peng L, Fang Z, Renauer PA, McNamara A, Park JJ, Lin Q, Zhou X, Dong MB, Zhu B, Zhao H, Wilen CB, Chen S. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Reports. 40: 111160. PMID 35921835 DOI: 10.1016/j.celrep.2022.111160 |
0.576 |
|
| 2022 |
Peng L, Renauer PA, Ökten A, Fang Z, Park JJ, Zhou X, Lin Q, Dong MB, Filler R, Xiong Q, Clark P, Lin C, Wilen CB, Chen S. Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2. Cell Reports. Medicine. 100634. PMID 35561673 DOI: 10.1016/j.xcrm.2022.100634 |
0.622 |
|
| 2022 |
Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, et al. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Nature Communications. 13: 1638. PMID 35347138 DOI: 10.1038/s41467-022-29288-3 |
0.744 |
|
| 2022 |
Ye L, Park JJ, Peng L, Yang Q, Chow RD, Dong MB, Lam SZ, Guo J, Tang E, Zhang Y, Wang G, Dai X, Du Y, Kim HR, Cao H, et al. A genome-scale gain-of-function CRISPR screen in CD8 T cells identifies proline metabolism as a means to enhance CAR-T therapy. Cell Metabolism. PMID 35276062 DOI: 10.1016/j.cmet.2022.02.009 |
0.771 |
|
| 2021 |
Peng L, Hu Y, Mankowski MC, Ren P, Chen RE, Wei J, Zhao M, Li T, Tripler T, Ye L, Chow RD, Fang Z, Wu C, Dong MB, Cook M, et al. Monospecific and bispecific monoclonal SARS-CoV-2 neutralizing antibodies that maintain potency against B.1.617. Biorxiv : the Preprint Server For Biology. PMID 34981065 DOI: 10.1101/2021.12.21.473733 |
0.743 |
|
| 2021 |
Dong MB, Tang K, Zhou X, Zhou JJ, Chen S. Tumor immunology CRISPR screening: present, past, and future. Trends in Cancer. PMID 34920978 DOI: 10.1016/j.trecan.2021.11.009 |
0.664 |
|
| 2020 |
Yuan S, Peng L, Park JJ, Hu Y, Devarkar SC, Dong MB, Shen Q, Wu S, Chen S, Lomakin IB, Xiong Y. Nonstructural Protein 1 of SARS-CoV-2 Is a Potent Pathogenicity Factor Redirecting Host Protein Synthesis Machinery toward Viral RNA. Molecular Cell. PMID 33188728 DOI: 10.1016/j.molcel.2020.10.034 |
0.55 |
|
| 2020 |
Wang G, Chow RD, Zhu L, Bai Z, Ye L, Zhang F, Renauer PA, Dong MB, Dai X, Zhang X, Du Y, Cheng Y, Niu L, Chu Z, Kim K, et al. CRISPR-GEMM pooled mutagenic screening identifies KMT2D as a major modulator of immune checkpoint blockade. Cancer Discovery. PMID 32887696 DOI: 10.1158/2159-8290.Cd-19-1448 |
0.78 |
|
| 2019 |
Wang G, Chow RD, Bai Z, Zhu L, Errami Y, Dai X, Dong MB, Ye L, Zhang X, Renauer PA, Park JJ, Shen L, Ye H, Fuchs CS, Chen S. Multiplexed activation of endogenous genes by CRISPRa elicits potent antitumor immunity. Nature Immunology. PMID 31611701 DOI: 10.1038/S41590-019-0500-4 |
0.777 |
|
| 2019 |
Ye L, Park JJ, Dong MB, Yang Q, Chow RD, Peng L, Du Y, Guo J, Dai X, Wang G, Errami Y, Chen S. In vivo CRISPR screening in CD8 T cells with AAV-Sleeping Beauty hybrid vectors identifies membrane targets for improving immunotherapy for glioblastoma. Nature Biotechnology. PMID 31548728 DOI: 10.1038/S41587-019-0246-4 |
0.772 |
|
| 2019 |
Dong MB, Wang G, Chow RD, Ye L, Zhu L, Dai X, Park JJ, Kim HR, Errami Y, Guzman CD, Zhou X, Chen KY, Renauer PA, Du Y, Shen J, et al. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells. Cell. 178: 1189-1204.e23. PMID 31442407 DOI: 10.1016/J.Cell.2019.07.044 |
0.781 |
|
| 2019 |
Chow RD, Wang G, Ye L, Codina A, Kim HR, Shen L, Dong MB, Errami Y, Chen S. In vivo profiling of metastatic double knockouts through CRISPR-Cpf1 screens. Nature Methods. PMID 30962622 DOI: 10.1038/S41592-019-0371-5 |
0.763 |
|
| 2019 |
Codina A, Renauer PA, Wang G, Chow RD, Park JJ, Ye H, Zhang K, Dong MB, Gassaway B, Ye L, Errami Y, Shen L, Chang A, Jain D, Herbst RS, et al. Convergent Identification and Interrogation of Tumor-Intrinsic Factors that Modulate Cancer Immunity In Vivo. Cell Systems. PMID 30797773 DOI: 10.1016/J.Cels.2019.01.004 |
0.804 |
|
| 2018 |
Wang G, Chow RD, Ye L, Guzman CD, Dai X, Dong MB, Zhang F, Sharp PA, Platt RJ, Chen S. Mapping a functional cancer genome atlas of tumor suppressors in mouse liver using AAV-CRISPR-mediated direct in vivo screening. Science Advances. 4: eaao5508. PMID 29503867 DOI: 10.1126/Sciadv.Aao5508 |
0.761 |
|
| 2017 |
Chow RD, Guzman CD, Wang G, Schmidt F, Youngblood MW, Ye L, Errami Y, Dong MB, Martinez MA, Zhang S, Renauer P, Bilguvar K, Gunel M, Sharp PA, Zhang F, et al. AAV-mediated direct in vivo CRISPR screen identifies functional suppressors in glioblastoma. Nature Neuroscience. PMID 28805815 DOI: 10.1038/Nn.4620 |
0.783 |
|
| Show low-probability matches. |